Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

Pricing
Back to Stakeholders
Care Delivery & Psychedelic FacilitationClinical Care Delivery OrganizationsHealth Systems & Hospitals
Care Delivery & Psychedelic FacilitationClinical Care Delivery Organizations
Care Delivery & Psychedelic Facilitation

Minneapolis Veterans Affairs Medical Center

United States
4 Trials

VA medical center in Minneapolis providing healthcare and clinical research for veterans. Part of the Veterans Health Administration network that has committed significant funding to studying MDMA- and psilocybin-assisted therapies for PTSD and treatment-resistant depression in veteran populations.

Quick Facts

Type
Other
HQ
United States
Website
Visit

Sponsored Trials

3
Not yet recruitingI, II

Psilocybin to Treat Depression in Spinal Cord Injury

Start Date
January 1, 2026
Compounds
Psilocybin
Not yet recruitingII

Ketamine Treatment for PTSD and MDD in TBI

Start Date
March 1, 2024
Compounds
Ketamine, Placebo
CompletedI

Ketamine Infusions for PTSD and Treatment-Resistant Depression

Start Date
January 5, 2015
Compounds
Ketamine

Collaborated Trials

1
CompletedI

Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans

Start Date
September 30, 2019
Compounds
Ketamine, Placebo

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.